Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis
Open Access
- 1 May 2008
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 93 (5), 1774-1783
- https://doi.org/10.1210/jc.2007-2768
Abstract
Context: Male hormonal contraceptive methods require effective suppression of sperm output. Objective: The objective of the study was to define the covariables that influence the rate and extent of suppression of spermatogenesis to a level shown in previous World Health Organization-sponsored studies to be sufficient for contraceptive purposes (≤1 million/ml). Design: This was an integrated analysis of all published male hormonal contraceptive studies of at least 3 months' treatment duration. Setting: Deidentified individual subject data were provided by investigators of 30 studies published between 1990 and 2006. Participants: A total of 1756 healthy men (by physical, blood, and semen exam) aged 18–51 yr of predominantly Caucasian (two thirds) or Asian (one third) descent were studied. This represents about 85% of all the published data. Intervention(s): Men were treated with different preparations of testosterone, with or without various progestins. Main Outcome Measure: Semen analysis was the main measure. Results: Progestin coadministration increased both the rate and extent of suppression. Caucasian men suppressed sperm output faster initially but ultimately to a less complete extent than did non-Caucasians. Younger age and lower initial blood testosterone or sperm concentration were also associated with faster suppression, but the independent effect sizes for age and baseline testicular function were relatively small. Conclusion: Male hormonal contraceptives can be practically applied to a wide range of men but require coadministration of an androgen with a second agent (i.e. progestin) for earlier and more complete suppression of sperm output. Whereas considerable progress has been made toward defining clinically effective combinations, further optimization of androgen-progestin treatment regimens is still required.Keywords
This publication has 77 references indexed in Scilit:
- Pharmacokinetics of Testosterone Undecanoate Injected Alone or in Combination With Norethisterone Enanthate in Healthy MenJournal of Andrology, 2006
- Advances in male hormonal contraceptionExpert Opinion on Investigational Drugs, 2006
- Drug Insight: recent advances in male hormonal contraceptionNature Clinical Practice Endocrinology & Metabolism, 2006
- Intramuscular Testosterone Enanthate Plus Very Low Dosage Oral Levonorgestrel Suppresses Spermatogenesis Without Causing Weight Gain in Normal Young Men: A Randomized Clinical TrialJournal of Andrology, 2005
- Hopes for male contraceptionThe Lancet, 2005
- Sixth Summit Meeting Consensus: Recommendations for Regulatory Approval for Hormonal Male ContraceptionInternational Journal of Andrology, 2002
- Rates of testosterone‐induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studiesInternational Journal of Andrology, 1995
- Direct effect of plasma sex hormone binding globulin (SHBG) on the metabolic clearance rate of 17β-estradiol in the primateJournal of Steroid Biochemistry, 1990
- Sustained inhibition of sperm production and inhibin secretion induced by a gonadotrophin-releasing hormone antagonist and delayed testosterone substitution in non-human primates (Macaca fascicularis)Journal of Endocrinology, 1989
- Disappearance of spermatozoa from ejaculate after vasectomy.BMJ, 1979